-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $28

Benzinga·03/12/2025 14:23:20
Listen to the news
Wedbush analyst Laura Chico maintains Astria Therapeutics (NASDAQ:ATXS) with a Outperform and raises the price target from $27 to $28.